Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 814-217-0 | CAS number: 353258-35-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- up-and-down procedure
- Limit test:
- no
Test material
- Reference substance name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
- Cas Number:
- 353258-35-2
- Molecular formula:
- C9H4ClF3N2O2
- IUPAC Name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
1
- Specific details on test material used for the study:
- Test substance: IN-QEK31-011
Batch No.: SG0312574
Purity: 98.2%
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories International, Inc., Raleigh, North Carolina, U.S.A.
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: 10-11 weeks
- Weight at study initiation: 211.5–248.6 g
- Fasting period before study: Approximately 17-17.25 hours prior to dosing, with food being returned to the rats approximately 3 hours after dosing.
- Housing: Animals were housed individually in solid-bottom caging with bedding and appropriate species-specific enrichment.
- Diet: ad libitum, except during fasting
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20-25ºC (68-77ºF)
- Humidity: 30-70%
- Air changes (per hr): Not reported
- Photoperiod: 12-hour light/dark cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.1% Tween 80 (v/v) in 0.5% methylcellulose
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage): 20 mL/kg/bw
MAXIMUM DOSE VOLUME APPLIED: 20 mL/kg/bw
DOSAGE PREPARATION (if unusual): IN-QEK31 was suspended in 0.1% Tween 80 (v/v) in 0.5% methylcellulose
- Doses:
- 550, 1750 or 5000 mg/kg bw
- No. of animals per sex per dose:
- 500 mg/kg bw: 2
1750 mg/kg bw: 3
5000 mg/kg bw: 1 - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Daily animal health observations were conducted throughout the study for mortality and signs of illness, injury, or abnormal behavior. Animals were weighed on test days -1, 1, 8, and 15, and were observed for clinical signs at the beginning of fasting, just before dosing (test day 1), once during the first 30 minutes after dosing and at least 2 more times on the day of dosing, and once each day thereafter.
- Necropsy of survivors performed: Yes - Statistics:
- A software package (AOT425StatPgm) was used to determine the dose progression and to estimate the LD50.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 750 mg/kg bw
- Based on:
- test mat.
- Mortality:
- At 550 mg/kg, both animals survived to scheduled sacrifice. Mortality occurred in 2/3 animals at 1750 mg/kg on test day 2 or 3, and in the one animal administered 5000 mg/kg on test day 1.
- Clinical signs:
- lethargy (hypoactivity)
- other:
- Body weight:
- other body weight observations
- Remarks:
- There were no overall (test day 1-15) body weight losses among any animals surviving to scheduled sacrifice.
- Gross pathology:
- No gross findings were observed in the animals administered 550 mg/kg or 5000 mg/kg.
Gross findings were present in all 3 animals administered 1750 mg/kg of test substance; 2 found dead prior to scheduled sacrifice and 1 at scheduled sacrifice. The 2 found dead rats had multiple ulcers and erosions in the glandular portion of the stomach. This lesion is presumed to be related to test substance administration. The remainder of the gross lesions observed within this study are nonspecific: one found dead rat also had bright red discoloration of the lungs; one found dead rat had bilateral chromodacryorrhea and multiple dark foci in the thymus; and one scheduled sacrifice rat had minimal diffuse dark discoloration of the lung. No other gross findings were observed.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- LD50 (rat): 1750 mg/kg bw
- Executive summary:
The study was conducted following OECD guideline 425 and US EPA OPPTS 870.1100. A single dose of IN-QEK31 was administered by oral gavage to fasted female rats at a dose level of 550, 1750 or 5000 mg/kg. The rats were dosed one at a time, at a minimum of 48-hour intervals. All rats were observed for mortality, body weight effects, and clinical signs for 14 days after dosing. The rats were necropsied to detect grossly observable evidence of organ or tissue damage.
At 550 mg/kg, both animals survived to scheduled sacrifice, with no clinical abnormalities or body weight losses. Mortality occurred in 2/3 animals at 1750 mg/kg on test day 2 or 3, and in the one animal administered 5000 mg/kg on test day 1. Clinical abnormalities observed in the early decedents included abnormal redness in ears and paws, loss of righting reflex, abnormal gait, labored breathing, coldness to touch, dehydration, decreased fecal output, ptosis, abnormal posture (high), piloerection, hypoactivity, prostration, decreased muscle tone, and/or moribundity. The surviving animal at 1750 mg/kg exhibited piloerection and hypoactivity, which resolved by test day 2, and did not exhibit overall (test day 1-15) body weight loss.
No gross findings were observed in the animals administered 550 mg/kg or 5000 mg/kg.
Gross findings were present in all 3 animals administered 1750 mg/kg of test substance; 2 found dead prior to scheduled sacrifice and 1 at scheduled sacrifice. The 2 found dead rats had multiple ulcers and erosions in the glandular portion of the stomach. This lesion is presumed to be related to test substance administration. The remainder of the gross lesions observed within this study are nonspecific: one found dead rat also had bright red discoloration of the lungs; one found dead rat had bilateral chromodacryorrhea and multiple dark foci in the thymus; and one scheduled sacrifice rat had minimal diffuse dark discoloration of the lung. No other gross findings were observed.
Under the conditions of this study, the oral LD50 for IN-QEK31 was 1750 mg/kg for female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.